Table 2.
Clinical characteristics and plasma carbamylated lipoproteins in individuals with diabetes with eGFR >60 ml/min per 1.73 m2 and the nondiabetic control group
| Characteristic | Control | Diabetes |
|---|---|---|
| N | 228 | 213 |
| Age, yr | 48±7 | 48±6 |
| Men/women, % | 50/50 | 49/51 |
| BMI, kg/m2 | 25±3 | 26±4 |
| Smoker, % | 14 | 12 |
| Duration of diabetes, yr | — | 9 (6–14) |
| Lipid-lowering therapy, % | — | 0 |
| Fasting glucose, mg/dl | 87±9 | 158±55 |
| HbA1c, % | 5.6±0.5 | 8.5±1.6 |
| eGFR, ml/min per 1.73 m2 | 81±12 | 83±16 |
| Total cholesterol, mg/dl | 189±26 | 189±31 |
| Triglyceride, mg/dl | 89 (62–124) | 115 (80–177) |
| LDL cholesterol, mg/dl | 112±24 | 113±28 |
| HDL cholesterol, mg/dl | 55±14 | 48±12 |
| Carbamylated LDL, µg/ml | 267 (171–388) | 340 (214–548) |
| Carbamylated HDL, µg/ml | 26±10 | 31±12 |
Data are expressed as mean±SD or median (interquartile range). BMI, body mass index; —, not applicable; HbA1c, hemoglobin A1c.